30 results about "Genomic Stability" patented technology

The present invention provides recombination based methods for assembling nucleic acids. In certain aspects the present invention provides hierarchical assembly methods for producing genome sized polynucleotide constructs. The methods may be used for assembling large polynucleotide constructs, for synthesizing synthetic genomes, or for introducing a plurality of nucleotide changes throughout the genome of an organism. In another aspect, the invention provides cells having increased genomic stability. For example, cells comprising alterations in at least a substantial portion of the transposons in the genome are provided.

This invention relates to the methods and pharmaceutical compositions for treating diseases or disorders associated with oxidative stress and/or genomic instability. In particular, the invention relates to methods for treating ataxia-telangeictasia (AT) and such disease states by administering a therapeutically effective amount of a chelating agent to increase genomic stability and/or decrease oxidative stress.

The invention relates to a method and a test kit for determining genome instability on the basis of a next-generation sequencing technology, belonging to the technical field of molecular detection. Inorder to overcome the defect that genome structure variation is not considered during detection of homologous recombination defects in the prior art, the invention provides the method and the test kit for determining genome instability on the basis of the next-generation sequencing technology. The method comprises the following steps: breaking a to-be-detected gene, then adding an A connector fora corresponding PCR reaction, carrying out hybridization capture through a designed probe, then amplifying a captured DNA library, sequencing the library, and carrying out evaluating through a software so as to determine the homologous recombination defect state. Compared with the prior art, the method provided by the invention can comprehensively evaluate the HRD state, is reliable in data results and is applicable to popularization.

The invention provides a kit for measuring genome instability and application thereof, and a probe set contained in the kit is determined by the following steps: dividing a reference genome sequence into a plurality of first-level regions, wherein the first-level regions contain at least one known SNP site; performing SNP filtering on each of the plurality of primary regions; selecting a notch region; dividing the gap region into at least one secondary region based on an expected interval; for each of the at least one secondary region, respectively carrying out secondary high-frequency SNP search: carrying out extension treatment from the central point of the secondary region to two sides for at least one time, and after extending for a preset length for at least one time, searching for the SNP with the highest frequency in the obtained region, and determining a third-level region on the basis of taking the summary of the first-level high-frequency SNP and the second-level high-frequency SNP as the starting point SNP; and based on the third-level region, constructing a probe for specifically identifying the third-level region. By utilizing the method, the probe combination which can be effectively used for analyzing the instability of the genome can be effectively obtained.

The invention relates to a method for constructing a target set for homologous recombination repair defect detection. The target set comprises a homologous recombination repair (HRR) gene and SNP (Single Nucleotide Polymorphism) loci, the HRR gene comprises 40 genes represented by BRCA1 and BRCA2, and the SNP loci comprise 10913 SNP loci. The SNP loci capable of fully representing genome instability are screened and combined with the HRR gene to construct the target set, the probe composition is designed, HRR gene variation can be detected by utilizing the probe composition, meanwhile, genome instability is accurately evaluated, the positive detection rate of homologous recombination repair defects can be effectively increased. The detection cost is reduced.

The invention provides a gene knock-in composition containing a single incision enzyme or polynucleotide coding the same, recombinase or polynucleotide coding the same, and an optional donor DNA containing an exogenous gene. The invention also provides a corresponding gene knock-in method and a method for preparing a transgenic non-human mammal model. The composition and the methods provided by the invention can be used for realizing efficient homologous recombination integration, and meanwhile various defects of insertion or deletion, genome instability and the like which are generated easily in the prior art can be avoided.

Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.

The present application relates to methods and compositions for the generation of therapeutic cells having reduced incidence of karyotypic abnormalities. In several embodiments cardiac stem cells are cultured in an antioxidant-supplemented media that reduces levels of reactive oxygen species, but does not down regulate DNA repair mechanisms. In several embodiments, physiological oxygen concentrations are used during culture in order to increase the proliferation of stem cells, decrease the senescence of the cells, decrease genomic instability, and/or augment the functionality of such cells for cellular therapies.

The purification of native RB (retinoblastoma) as a complex, including P107, P130, and a 600 kDa subunit, termed MTAF600 (microtubule associated factor 600) is described. MTAF600 binds to RB regardless of the phosphorylation status of RB, and binds to RB without disrupting the interaction between RB and E2F. It is further shown that E2F and DP proteins co-purified with MTAF600 and RB, such that hypophosphorylated RB may gain access to E2F as a complex with MTAF600. In addition, MTAF600 binds to microtubules and plays a role in active repression of E2F-responsive genes, cell cycle arrest, and genomic stability. The sequence of MTAF600 is described herein, along with its binding properties to proteins such as RB and microtubules, and its sequence homology. Further, methods and reagents for assaying the presence of MTAF600 or mutants thereof, pharmaceutical formulations, and methods for treating disease are also described.

The present application relates to methods and compositions for the generation of therapeutic cells having reduced incidence of karyotypic abnormalities. In several embodiments cardiac stem cells are cultured in an antioxidant-supplemented media that reduces levels of reactive oxygen species, but does not down regulate DNA repair mechanisms. In several embodiments, physiological oxygen concentrations are used during culture in order to increase the proliferation of stem cells, decrease the senescence of the cells, decrease genomic instability, and/or augment the functionality of such cells for cellular therapies.

Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.

The present disclosure relates to methods and compositions for producing induced pluripotent stem cells with improved efficiency and genomic stability. In particular aspects, induced pluripotent stem cells are produced from somatic cells after inhibiting, lowering, or down-regulating a particular protein or gene. In some embodiments, the protein is a p53-binding protein or 53BP1.

The invention discloses C-terminal specific human Eme1 polypeptide, as well as an antibody and a preparation method thereof, belonging to the biomedicine technical field. The amino acid sequence of the C-terminal specific human Eme1 polypeptide is VRRGEGVTSTSRRIG.. Antihuman EME1 polypeptide antibody is prepared according to the following method that: (1) human EME1 epitope is analyzed; (2) human EME1 C-terminal polypeptide is synthesized; (3) synthesized polypeptide is crosslinked with carrier protein; (4) rabbit anti-human EME1 polypeptide antibody is prepared; (5) serum containing the antibody is obtained through collection and separation, and the antibody is purified, and then the antihuman EME1 polypeptide antibody can be obtained. The C-terminal specific antihuman BTRC synthesized polypeptide antibody is high in potency, strong in affinity, good in specificity, capable of having specific conjugation with natural human Eme1; purified antibody can be completely used for immunoblot and enzyme linked immunosorbent assay, as well as the establishment of in vitro immunization analytical method. The antibody provides a useful tool for the research on the biological effects of Eme1 in DNA damage and genomic stability.

The invention discloses N-terminal specific human Eme1 polypeptide, as well as an antibody and a preparation method thereof, belonging to the biomedicine technical field. The amino acid sequence of the N-terminal specific human Eme1 polypeptide is LKKEPSSTKRRQPER. Antihuman EME1 polypeptide antibody is prepared according to the following method that: (1) human EME1 epitope is analyzed; (2) human EME1 N-terminal polypeptide is synthesized; (3) synthesized polypeptide is crosslinked with carrier protein; (4) rabbit anti-human EME1 polypeptide antibody is prepared; (5) serum containing the antibody is obtained through collection and separation, and the antibody is purified, and then the antihuman EME1 polypeptide antibody can be obtained. The N-terminal specific antihuman BTRC synthesized polypeptide antibody is high in potency, strong in affinity, good in specificity, capable of having specific conjugation with natural human Eme1; purified antibody can be completely used for immunoblot and enzyme linked immunosorbent assay, as well as the establishment of in vitro immunization analytical method. The antibody provides a useful tool for the research on the biological effects of Eme1 in DNA damage and genomic stability.